Van Gool Michiel, Alonso De Diego Sergio A, Delgado Oscar, Trabanco Andrés A, Jourdan Fabrice, Macdonald Gregor J, Somers Marijke, Ver Donck Luc
Neuroscience, Janssen Research & Development, Jarama 75A, 45007, Toledo, Spain.
NovAliX Pharma, Jarama 75A, 45007, Toledo, Spain.
ChemMedChem. 2017 Jun 21;12(12):905-912. doi: 10.1002/cmdc.201700101. Epub 2017 Apr 10.
The metabotropic glutamate subtype 2 (mGlu ) receptor is a presynaptic membrane receptor distributed widely in brain that provides feedback inhibitory control of glutamate release. Inhibition of the mGlu receptor function with a negative allosteric modulator (NAM) enhances activity-dependent glutamate release, which may be of therapeutic benefit for the treatment of neurological and psychiatric disorders. An attractive pyrazole hit was identified after a high-throughput screening (HTS) campaign. The evolution of this hit is described by structure-activity relationship (SAR) studies on specific parts of the molecule. From near micromolar potency we could obtain compounds with single-digit nanomolar activity in the mGlu NAM GTPγS assay. In addition to SAR on in vitro potency, a more detailed overview is given with a specific set of compounds on the excellent agreement between in vitro potency, free brain concentration, and ex vivo mGlu receptor occupancy. Finally, to obtain improved drug-like compounds, plans for future research are suggested toward increasing free brain concentration while maintaining high in vitro potency.
代谢型谷氨酸2(mGlu)受体是一种广泛分布于大脑中的突触前膜受体,可对谷氨酸释放提供反馈抑制性控制。用负性变构调节剂(NAM)抑制mGlu受体功能可增强活性依赖性谷氨酸释放,这可能对治疗神经和精神疾病具有治疗益处。在一次高通量筛选(HTS)活动后鉴定出了一种有吸引力的吡唑命中化合物。通过对分子特定部分的构效关系(SAR)研究描述了这种命中化合物的演变。从接近微摩尔的效力,我们可以在mGlu NAM GTPγS测定中获得具有个位数纳摩尔活性的化合物。除了关于体外效力的SAR外,还给出了一组特定化合物在体外效力、游离脑浓度和体外mGlu受体占有率之间极佳一致性的更详细概述。最后,为了获得改进的类药物化合物,建议了未来的研究计划,以在保持高体外效力的同时提高游离脑浓度。